The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine.
Animal research · 1997
- What was studied
- Rat metabolism and enzyme preparations
- Main finding
- Rat-brain CPG increased approximately 2.5-fold one hour after GVS-111 administration. Enzyme experiments supported conversion to CPG; these findings do not prove that CPG accounts for every Noopept effect.
Study data at a glance
- Participants or experimental model
- Rat metabolism and enzyme preparations
- Reported results
- Rat-brain CPG increased approximately 2.5-fold one hour after GVS-111 administration. Enzyme experiments supported conversion to CPG; these findings do not prove that CPG accounts for every Noopept effect.
Study limitations and source details
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Source details
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Abstract reviewed
Sources checked
Citation
Gudasheva TA, Boyko SS, Ostrovskaya RU, Voronina TA, Akparov VK, Trofimov SS, Rozantsev GG, Skoldinov AP, Zherdev VP, Seredenin SB. The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine. European journal of drug metabolism and pharmacokinetics
Study source ↗ · DOI 10.1007/bf03189814 · Bibliography entry · Link to this summary
Related compounds
CPG & GZK-111
Cycloprolylglycine (CPG) is a naturally occurring cyclic dipeptide formed from proline and glycine. GZK-111 is an experimental linear precursor. CPG has also been measured as a metabolite of Noopept.
Noopept
Omberacetam (GVS-111), a synthetic derivative of the Pro–Gly dipeptide. Its chemical name is N-phenylacetyl-L-prolylglycine ethyl ester. Studies examined cognition and the metabolite cycloprolylglycine.